#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Cytosine DNA methylation ( 5-methylcytosine ; 5mC , CDM ) is one of the most well-studied epigenomic marks and mechanistically understood epigenetic modifications to date .
2-1	16-24	Cytosine	abstract|abstract[4]	new|new[4]	appos|coref	2-5[0_4]|10-17
2-2	25-28	DNA	abstract|abstract[4]	new|new[4]	coref	4-16
2-3	29-40	methylation	abstract[4]	new[4]	_	_
2-4	41-42	(	_	_	_	_
2-5	43-59	5-methylcytosine	abstract	giv	appos	2-7
2-6	60-61	;	_	_	_	_
2-7	62-65	5mC	abstract	giv	appos	2-9
2-8	66-67	,	_	_	_	_
2-9	68-71	CDM	abstract	giv	coref	4-26[32_0]
2-10	72-73	)	_	_	_	_
2-11	74-76	is	_	_	_	_
2-12	77-80	one	abstract[8]	new[8]	ana	3-1[0_8]
2-13	81-83	of	abstract[8]	new[8]	_	_
2-14	84-87	the	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-15	88-92	most	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-16	93-105	well-studied	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-17	106-116	epigenomic	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-18	117-122	marks	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-19	123-126	and	abstract[8]	new[8]	_	_
2-20	127-142	mechanistically	abstract[8]|abstract[10]	new[8]|new[10]	_	_
2-21	143-153	understood	abstract[8]|abstract[10]	new[8]|new[10]	_	_
2-22	154-164	epigenetic	abstract[8]|abstract[10]	new[8]|new[10]	_	_
2-23	165-178	modifications	abstract[8]|abstract[10]	new[8]|new[10]	_	_
2-24	179-181	to	abstract[8]	new[8]	_	_
2-25	182-186	date	abstract[8]|time	new[8]|new	_	_
2-26	187-188	.	_	_	_	_

#Text=It plays important roles in various biological processes , including X-chromosome inactivation , genomic imprinting , transposon suppression and transcriptional regulation .
3-1	189-191	It	abstract	giv	_	_
3-2	192-197	plays	_	_	_	_
3-3	198-207	important	abstract[13]	new[13]	_	_
3-4	208-213	roles	abstract[13]	new[13]	_	_
3-5	214-216	in	abstract[13]	new[13]	_	_
3-6	217-224	various	abstract[13]|abstract[14]	new[13]|new[14]	coref	18-21[160_14]
3-7	225-235	biological	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-8	236-245	processes	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-9	246-247	,	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-10	248-257	including	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-11	258-270	X-chromosome	abstract[13]|abstract[14]|abstract|event[16]	new[13]|new[14]|new|new[16]	_	_
3-12	271-283	inactivation	abstract[13]|abstract[14]|event[16]	new[13]|new[14]|new[16]	_	_
3-13	284-285	,	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-14	286-293	genomic	abstract[13]|abstract[14]|abstract[17]	new[13]|new[14]|new[17]	_	_
3-15	294-304	imprinting	abstract[13]|abstract[14]|abstract[17]	new[13]|new[14]|new[17]	_	_
3-16	305-306	,	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-17	307-317	transposon	abstract[13]|abstract[14]|time|event[19]	new[13]|new[14]|new|new[19]	_	_
3-18	318-329	suppression	abstract[13]|abstract[14]|event[19]	new[13]|new[14]|new[19]	_	_
3-19	330-333	and	abstract[13]|abstract[14]	new[13]|new[14]	_	_
3-20	334-349	transcriptional	abstract[13]|abstract[14]|abstract[20]	new[13]|new[14]|new[20]	_	_
3-21	350-360	regulation	abstract[13]|abstract[14]|abstract[20]	new[13]|new[14]|new[20]	_	_
3-22	361-362	.	_	_	_	_

#Text=Technological improvements and dramatic cost reductions for whole-genome sodium bisulfite sequencing ( WGBS ) of DNA have opened the door to the quantitative measurement of DNA methylation at a single base resolution , with datasets now available from numerous species .
4-1	363-376	Technological	abstract[21]	new[21]	_	_
4-2	377-389	improvements	abstract[21]	new[21]	_	_
4-3	390-393	and	_	_	_	_
4-4	394-402	dramatic	abstract[23]	new[23]	_	_
4-5	403-407	cost	abstract|abstract[23]	new|new[23]	_	_
4-6	408-418	reductions	abstract[23]	new[23]	_	_
4-7	419-422	for	abstract[23]	new[23]	_	_
4-8	423-435	whole-genome	abstract[23]|abstract[26]	new[23]|new[26]	appos	4-13[0_26]
4-9	436-442	sodium	abstract[23]|substance|abstract[25]|abstract[26]	new[23]|new|new[25]|new[26]	coref	10-22[0_25]
4-10	443-452	bisulfite	abstract[23]|abstract[25]|abstract[26]	new[23]|new[25]|new[26]	_	_
4-11	453-463	sequencing	abstract[23]|abstract[26]	new[23]|new[26]	_	_
4-12	464-465	(	_	_	_	_
4-13	466-470	WGBS	abstract	giv	coref	10-23
4-14	471-472	)	_	_	_	_
4-15	473-475	of	_	_	_	_
4-16	476-479	DNA	abstract	giv	coref	4-26
4-17	480-484	have	_	_	_	_
4-18	485-491	opened	_	_	_	_
4-19	492-495	the	object[29]	new[29]	_	_
4-20	496-500	door	object[29]	new[29]	_	_
4-21	501-503	to	object[29]	new[29]	_	_
4-22	504-507	the	object[29]|abstract[30]	new[29]|new[30]	_	_
4-23	508-520	quantitative	object[29]|abstract[30]	new[29]|new[30]	_	_
4-24	521-532	measurement	object[29]|abstract[30]	new[29]|new[30]	_	_
4-25	533-535	of	object[29]|abstract[30]	new[29]|new[30]	_	_
4-26	536-539	DNA	object[29]|abstract[30]|abstract|abstract[32]	new[29]|new[30]|giv|giv[32]	coref|coref	5-5[0_32]|6-3
4-27	540-551	methylation	object[29]|abstract[30]|abstract[32]	new[29]|new[30]|giv[32]	_	_
4-28	552-554	at	object[29]|abstract[30]	new[29]|new[30]	_	_
4-29	555-556	a	object[29]|abstract[30]|abstract[34]	new[29]|new[30]|new[34]	coref	14-21[112_34]
4-30	557-563	single	object[29]|abstract[30]|place[33]|abstract[34]	new[29]|new[30]|new[33]|new[34]	_	_
4-31	564-568	base	object[29]|abstract[30]|place[33]|abstract[34]	new[29]|new[30]|new[33]|new[34]	_	_
4-32	569-579	resolution	object[29]|abstract[30]|abstract[34]	new[29]|new[30]|new[34]	_	_
4-33	580-581	,	_	_	_	_
4-34	582-586	with	_	_	_	_
4-35	587-595	datasets	abstract	new	_	_
4-36	596-599	now	_	_	_	_
4-37	600-609	available	_	_	_	_
4-38	610-614	from	_	_	_	_
4-39	615-623	numerous	animal[36]	new[36]	_	_
4-40	624-631	species	animal[36]	new[36]	_	_
4-41	632-633	.	_	_	_	_

#Text=In humans , significant methylation differences are observed in the white blood cells of matched monozygotic and dizygotic twins , and significant intra- and inter-population differential methylation has been identified in a study of three human populations ( Caucasian-American , African-American and Chinese-American ) .
5-1	634-636	In	_	_	_	_
5-2	637-643	humans	animal	new	_	_
5-3	644-645	,	_	_	_	_
5-4	646-657	significant	abstract[39]	new[39]	_	_
5-5	658-669	methylation	abstract|abstract[39]	giv|new[39]	coref	5-22[43_0]
5-6	670-681	differences	abstract[39]	new[39]	_	_
5-7	682-685	are	_	_	_	_
5-8	686-694	observed	_	_	_	_
5-9	695-697	in	_	_	_	_
5-10	698-701	the	object[41]	new[41]	_	_
5-11	702-707	white	object[41]	new[41]	_	_
5-12	708-713	blood	substance|object[41]	new|new[41]	_	_
5-13	714-719	cells	object[41]	new[41]	_	_
5-14	720-722	of	object[41]	new[41]	_	_
5-15	723-730	matched	object[41]|animal[42]	new[41]|new[42]	_	_
5-16	731-742	monozygotic	object[41]|animal[42]	new[41]|new[42]	_	_
5-17	743-746	and	object[41]|animal[42]	new[41]|new[42]	_	_
5-18	747-756	dizygotic	object[41]|animal[42]	new[41]|new[42]	_	_
5-19	757-762	twins	object[41]|animal[42]	new[41]|new[42]	_	_
5-20	763-764	,	_	_	_	_
5-21	765-768	and	_	_	_	_
5-22	769-780	significant	abstract[43]	giv[43]	coref	6-3[47_43]
5-23	781-787	intra-	abstract[43]	giv[43]	_	_
5-24	788-791	and	abstract[43]	giv[43]	_	_
5-25	792-808	inter-population	abstract[43]	giv[43]	_	_
5-26	809-821	differential	abstract[43]	giv[43]	_	_
5-27	822-833	methylation	abstract[43]	giv[43]	_	_
5-28	834-837	has	_	_	_	_
5-29	838-842	been	_	_	_	_
5-30	843-853	identified	_	_	_	_
5-31	854-856	in	_	_	_	_
5-32	857-858	a	abstract[44]	new[44]	_	_
5-33	859-864	study	abstract[44]	new[44]	_	_
5-34	865-867	of	abstract[44]	new[44]	_	_
5-35	868-873	three	abstract[44]|person[45]	new[44]|new[45]	coref	19-13[172_45]
5-36	874-879	human	abstract[44]|person[45]	new[44]|new[45]	_	_
5-37	880-891	populations	abstract[44]|person[45]	new[44]|new[45]	_	_
5-38	892-893	(	_	_	_	_
5-39	894-912	Caucasian-American	_	_	_	_
5-40	913-914	,	_	_	_	_
5-41	915-931	African-American	_	_	_	_
5-42	932-935	and	_	_	_	_
5-43	936-952	Chinese-American	_	_	_	_
5-44	953-954	)	_	_	_	_
5-45	955-956	.	_	_	_	_

#Text=Likewise , DNA methylation levels vary considerably in samples experiencing changes during development or in response to environmental change .
6-1	957-965	Likewise	_	_	_	_
6-2	966-967	,	_	_	_	_
6-3	968-971	DNA	abstract|abstract[47]|abstract[48]	giv|giv[47]|new[48]	coref|coref	7-6|7-6[56_47]
6-4	972-983	methylation	abstract[47]|abstract[48]	giv[47]|new[48]	_	_
6-5	984-990	levels	abstract[48]	new[48]	_	_
6-6	991-995	vary	_	_	_	_
6-7	996-1008	considerably	_	_	_	_
6-8	1009-1011	in	_	_	_	_
6-9	1012-1019	samples	object[49]	new[49]	coref	18-14[0_49]
6-10	1020-1032	experiencing	object[49]	new[49]	_	_
6-11	1033-1040	changes	object[49]|abstract[50]	new[49]|new[50]	coref	18-4[155_50]
6-12	1041-1047	during	object[49]|abstract[50]	new[49]|new[50]	_	_
6-13	1048-1059	development	object[49]|abstract[50]|event	new[49]|new[50]|new	coref	9-12[68_0]
6-14	1060-1062	or	_	_	_	_
6-15	1063-1065	in	_	_	_	_
6-16	1066-1074	response	_	_	_	_
6-17	1075-1077	to	_	_	_	_
6-18	1078-1091	environmental	event[52]	new[52]	coref	14-34[116_52]
6-19	1092-1098	change	event[52]	new[52]	_	_
6-20	1099-1100	.	_	_	_	_

#Text=Translation of the advances in DNA methylation to clinical and personalized medical contexts has been proposed .
7-1	1101-1112	Translation	abstract[53]	new[53]	_	_
7-2	1113-1115	of	abstract[53]	new[53]	_	_
7-3	1116-1119	the	abstract[53]|abstract[54]	new[53]|new[54]	_	_
7-4	1120-1128	advances	abstract[53]|abstract[54]	new[53]|new[54]	_	_
7-5	1129-1131	in	abstract[53]|abstract[54]	new[53]|new[54]	_	_
7-6	1132-1135	DNA	abstract[53]|abstract[54]|abstract|abstract[56]	new[53]|new[54]|giv|giv[56]	coref|coref	8-15[0_56]|18-24
7-7	1136-1147	methylation	abstract[53]|abstract[54]|abstract[56]	new[53]|new[54]|giv[56]	_	_
7-8	1148-1150	to	abstract[53]	new[53]	_	_
7-9	1151-1159	clinical	abstract[53]|abstract[57]	new[53]|new[57]	_	_
7-10	1160-1163	and	abstract[53]|abstract[57]	new[53]|new[57]	_	_
7-11	1164-1176	personalized	abstract[53]|abstract[57]	new[53]|new[57]	_	_
7-12	1177-1184	medical	abstract[53]|abstract[57]	new[53]|new[57]	_	_
7-13	1185-1193	contexts	abstract[53]|abstract[57]	new[53]|new[57]	_	_
7-14	1194-1197	has	_	_	_	_
7-15	1198-1202	been	_	_	_	_
7-16	1203-1211	proposed	_	_	_	_
7-17	1212-1213	.	_	_	_	_

#Text=Evidence of epigenetic alterations induced by disease emphasizes the significant potential value of high-resolution methylation pattern analysis .
8-1	1214-1222	Evidence	abstract[58]	new[58]	_	_
8-2	1223-1225	of	abstract[58]	new[58]	_	_
8-3	1226-1236	epigenetic	abstract[58]|abstract[59]	new[58]|new[59]	coref	9-24[71_59]
8-4	1237-1248	alterations	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-5	1249-1256	induced	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-6	1257-1259	by	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-7	1260-1267	disease	abstract[58]|abstract[59]|abstract	new[58]|new[59]|new	coref	9-29[72_0]
8-8	1268-1278	emphasizes	_	_	_	_
8-9	1279-1282	the	abstract[61]	new[61]	coref	26-6[227_61]
8-10	1283-1294	significant	abstract[61]	new[61]	_	_
8-11	1295-1304	potential	abstract[61]	new[61]	_	_
8-12	1305-1310	value	abstract[61]	new[61]	_	_
8-13	1311-1313	of	abstract[61]	new[61]	_	_
8-14	1314-1329	high-resolution	abstract[61]|abstract[64]	new[61]|new[64]	_	_
8-15	1330-1341	methylation	abstract[61]|abstract|abstract[63]|abstract[64]	new[61]|giv|new[63]|new[64]	coref	10-12
8-16	1342-1349	pattern	abstract[61]|abstract[63]|abstract[64]	new[61]|new[63]|new[64]	_	_
8-17	1350-1358	analysis	abstract[61]|abstract[64]	new[61]|new[64]	_	_
8-18	1359-1360	.	_	_	_	_

#Text=However , proper translation of this knowledge for diagnostics depends upon the development of genome-wide techniques for the rapid and robust identification of specific epigenetic alterations associated with the disease .
9-1	1361-1368	However	_	_	_	_
9-2	1369-1370	,	_	_	_	_
9-3	1371-1377	proper	abstract[65]	new[65]	_	_
9-4	1378-1389	translation	abstract[65]	new[65]	_	_
9-5	1390-1392	of	abstract[65]	new[65]	_	_
9-6	1393-1397	this	abstract[65]|abstract[66]	new[65]|new[66]	_	_
9-7	1398-1407	knowledge	abstract[65]|abstract[66]	new[65]|new[66]	_	_
9-8	1408-1411	for	abstract[65]	new[65]	_	_
9-9	1412-1423	diagnostics	abstract[65]|abstract	new[65]|new	_	_
9-10	1424-1431	depends	_	_	_	_
9-11	1432-1436	upon	_	_	_	_
9-12	1437-1440	the	event[68]	giv[68]	coref	22-35[197_68]
9-13	1441-1452	development	event[68]	giv[68]	_	_
9-14	1453-1455	of	event[68]	giv[68]	_	_
9-15	1456-1467	genome-wide	event[68]|abstract[69]	giv[68]|new[69]	_	_
9-16	1468-1478	techniques	event[68]|abstract[69]	giv[68]|new[69]	_	_
9-17	1479-1482	for	event[68]|abstract[69]	giv[68]|new[69]	_	_
9-18	1483-1486	the	event[68]|abstract[69]|abstract[70]	giv[68]|new[69]|new[70]	_	_
9-19	1487-1492	rapid	event[68]|abstract[69]|abstract[70]	giv[68]|new[69]|new[70]	_	_
9-20	1493-1496	and	event[68]|abstract[69]|abstract[70]	giv[68]|new[69]|new[70]	_	_
9-21	1497-1503	robust	event[68]|abstract[69]|abstract[70]	giv[68]|new[69]|new[70]	_	_
9-22	1504-1518	identification	event[68]|abstract[69]|abstract[70]	giv[68]|new[69]|new[70]	_	_
9-23	1519-1521	of	event[68]|abstract[69]|abstract[70]	giv[68]|new[69]|new[70]	_	_
9-24	1522-1530	specific	event[68]|abstract[69]|abstract[70]|abstract[71]	giv[68]|new[69]|new[70]|giv[71]	_	_
9-25	1531-1541	epigenetic	event[68]|abstract[69]|abstract[70]|abstract[71]	giv[68]|new[69]|new[70]|giv[71]	_	_
9-26	1542-1553	alterations	event[68]|abstract[69]|abstract[70]|abstract[71]	giv[68]|new[69]|new[70]|giv[71]	_	_
9-27	1554-1564	associated	event[68]|abstract[69]|abstract[70]|abstract[71]	giv[68]|new[69]|new[70]|giv[71]	_	_
9-28	1565-1569	with	event[68]|abstract[69]|abstract[70]|abstract[71]	giv[68]|new[69]|new[70]|giv[71]	_	_
9-29	1570-1573	the	event[68]|abstract[69]|abstract[70]|abstract[71]|abstract[72]	giv[68]|new[69]|new[70]|giv[71]|giv[72]	coref	15-24[0_72]
9-30	1574-1581	disease	event[68]|abstract[69]|abstract[70]|abstract[71]|abstract[72]	giv[68]|new[69]|new[70]|giv[71]|giv[72]	_	_
9-31	1582-1583	.	_	_	_	_

#Text=Currently , there are numerous available bioinformatics tools to estimate the methylation status of nearly every cytosine position within a whole-genome bisulfite sequencing dataset .
10-1	1584-1593	Currently	_	_	_	_
10-2	1594-1595	,	_	_	_	_
10-3	1596-1601	there	_	_	_	_
10-4	1602-1605	are	_	_	_	_
10-5	1606-1614	numerous	abstract[74]	new[74]	coref	11-1[82_74]
10-6	1615-1624	available	abstract[74]	new[74]	_	_
10-7	1625-1639	bioinformatics	abstract|abstract[74]	new|new[74]	_	_
10-8	1640-1645	tools	abstract[74]	new[74]	_	_
10-9	1646-1648	to	abstract[74]	new[74]	_	_
10-10	1649-1657	estimate	abstract[74]	new[74]	_	_
10-11	1658-1661	the	abstract[74]|abstract[76]	new[74]|new[76]	_	_
10-12	1662-1673	methylation	abstract[74]|abstract|abstract[76]	new[74]|giv|new[76]	coref	14-35
10-13	1674-1680	status	abstract[74]|abstract[76]	new[74]|new[76]	_	_
10-14	1681-1683	of	abstract[74]|abstract[76]	new[74]|new[76]	_	_
10-15	1684-1690	nearly	abstract[74]|abstract[76]|abstract[78]	new[74]|new[76]|new[78]	_	_
10-16	1691-1696	every	abstract[74]|abstract[76]|abstract[78]	new[74]|new[76]|new[78]	_	_
10-17	1697-1705	cytosine	abstract[74]|abstract[76]|abstract|abstract[78]	new[74]|new[76]|giv|new[78]	_	_
10-18	1706-1714	position	abstract[74]|abstract[76]|abstract[78]	new[74]|new[76]|new[78]	_	_
10-19	1715-1721	within	abstract[74]|abstract[76]|abstract[78]	new[74]|new[76]|new[78]	_	_
10-20	1722-1723	a	abstract[74]|abstract[76]|abstract[78]|abstract[81]	new[74]|new[76]|new[78]|new[81]	_	_
10-21	1724-1736	whole-genome	abstract[74]|abstract[76]|abstract[78]|abstract[81]	new[74]|new[76]|new[78]|new[81]	_	_
10-22	1737-1746	bisulfite	abstract[74]|abstract[76]|abstract[78]|abstract|abstract[81]	new[74]|new[76]|new[78]|giv|new[81]	_	_
10-23	1747-1757	sequencing	abstract[74]|abstract[76]|abstract[78]|abstract|abstract[81]	new[74]|new[76]|new[78]|giv|new[81]	_	_
10-24	1758-1765	dataset	abstract[74]|abstract[76]|abstract[78]|abstract[81]	new[74]|new[76]|new[78]|new[81]	_	_
10-25	1766-1767	.	_	_	_	_

#Text=These tools are generally supported by an application of robust statistical approaches ; DSS , BiSeq , and methylKit , among others , are ones that apply generalized linear regression ( beta-regression ) in the estimation of differentially methylated positions ( DMPs ) .
11-1	1768-1773	These	abstract[82]	giv[82]	_	_
11-2	1774-1779	tools	abstract[82]	giv[82]	_	_
11-3	1780-1783	are	_	_	_	_
11-4	1784-1793	generally	_	_	_	_
11-5	1794-1803	supported	_	_	_	_
11-6	1804-1806	by	_	_	_	_
11-7	1807-1809	an	abstract[83]	new[83]	coref	17-18[146_83]
11-8	1810-1821	application	abstract[83]	new[83]	_	_
11-9	1822-1824	of	abstract[83]	new[83]	_	_
11-10	1825-1831	robust	abstract[83]|abstract[84]	new[83]|new[84]	coref	14-1[105_84]
11-11	1832-1843	statistical	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-12	1844-1854	approaches	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-13	1855-1856	;	_	_	_	_
11-14	1857-1860	DSS	abstract	new	_	_
11-15	1861-1862	,	_	_	_	_
11-16	1863-1868	BiSeq	abstract	new	_	_
11-17	1869-1870	,	_	_	_	_
11-18	1871-1874	and	_	_	_	_
11-19	1875-1884	methylKit	object	new	coref	11-25[88_0]
11-20	1885-1886	,	_	_	_	_
11-21	1887-1892	among	_	_	_	_
11-22	1893-1899	others	_	_	_	_
11-23	1900-1901	,	_	_	_	_
11-24	1902-1905	are	_	_	_	_
11-25	1906-1910	ones	object[88]	giv[88]	coref	12-4[0_88]
11-26	1911-1915	that	object[88]	giv[88]	_	_
11-27	1916-1921	apply	object[88]	giv[88]	_	_
11-28	1922-1933	generalized	object[88]|abstract[89]	giv[88]|new[89]	appos	11-32[0_89]
11-29	1934-1940	linear	object[88]|abstract[89]	giv[88]|new[89]	_	_
11-30	1941-1951	regression	object[88]|abstract[89]	giv[88]|new[89]	_	_
11-31	1952-1953	(	object[88]	giv[88]	_	_
11-32	1954-1969	beta-regression	object[88]|abstract	giv[88]|giv	_	_
11-33	1970-1971	)	object[88]	giv[88]	_	_
11-34	1972-1974	in	object[88]	giv[88]	_	_
11-35	1975-1978	the	object[88]|abstract[91]	giv[88]|new[91]	coref	13-5[100_91]
11-36	1979-1989	estimation	object[88]|abstract[91]	giv[88]|new[91]	_	_
11-37	1990-1992	of	object[88]|abstract[91]	giv[88]|new[91]	_	_
11-38	1993-2007	differentially	object[88]|abstract[91]|abstract[92]	giv[88]|new[91]|new[92]	appos	11-42[0_92]
11-39	2008-2018	methylated	object[88]|abstract[91]|abstract[92]	giv[88]|new[91]|new[92]	_	_
11-40	2019-2028	positions	object[88]|abstract[91]|abstract[92]	giv[88]|new[91]|new[92]	_	_
11-41	2029-2030	(	_	_	_	_
11-42	2031-2035	DMPs	abstract	giv	coref	15-27[124_0]
11-43	2036-2037	)	_	_	_	_
11-44	2038-2039	.	_	_	_	_

#Text=In addition , methylKit provides the option to apply Fisher ’s exact test .
12-1	2040-2042	In	_	_	_	_
12-2	2043-2051	addition	_	_	_	_
12-3	2052-2053	,	_	_	_	_
12-4	2054-2063	methylKit	object	giv	_	_
12-5	2064-2072	provides	_	_	_	_
12-6	2073-2076	the	abstract[95]	new[95]	_	_
12-7	2077-2083	option	abstract[95]	new[95]	_	_
12-8	2084-2086	to	abstract[95]	new[95]	_	_
12-9	2087-2092	apply	abstract[95]	new[95]	_	_
12-10	2093-2099	Fisher	abstract[95]|person[96]|abstract[97]	new[95]|new[96]|new[97]	coref	13-11[103_97]
12-11	2100-2102	’s	abstract[95]|person[96]|abstract[97]	new[95]|new[96]|new[97]	_	_
12-12	2103-2108	exact	abstract[95]|abstract[97]	new[95]|new[97]	_	_
12-13	2109-2113	test	abstract[95]|abstract[97]	new[95]|new[97]	_	_
12-14	2114-2115	.	_	_	_	_

#Text=Alternatively , methylpy bases its estimation on the implementation of the root-mean-square test ( RMST ) .
13-1	2116-2129	Alternatively	_	_	_	_
13-2	2130-2131	,	_	_	_	_
13-3	2132-2140	methylpy	substance	new	ana	13-5
13-4	2141-2146	bases	_	_	_	_
13-5	2147-2150	its	substance|abstract[100]	giv|giv[100]	_	_
13-6	2151-2161	estimation	abstract[100]	giv[100]	_	_
13-7	2162-2164	on	_	_	_	_
13-8	2165-2168	the	event[101]	new[101]	_	_
13-9	2169-2183	implementation	event[101]	new[101]	_	_
13-10	2184-2186	of	event[101]	new[101]	_	_
13-11	2187-2190	the	event[101]|abstract[103]	new[101]|giv[103]	appos	13-15[0_103]
13-12	2191-2207	root-mean-square	event[101]|substance|abstract[103]	new[101]|new|giv[103]	_	_
13-13	2208-2212	test	event[101]|abstract[103]	new[101]|giv[103]	_	_
13-14	2213-2214	(	_	_	_	_
13-15	2215-2219	RMST	abstract	giv	_	_
13-16	2220-2221	)	_	_	_	_
13-17	2222-2223	.	_	_	_	_

#Text=Most of these approaches do not incorporate the influence of natural stochasticity ( randomness ) to their models , limiting their resolution predominantly to genomic regions with the highest probability of having undergone a methylation change .
14-1	2224-2228	Most	abstract[105]	giv[105]	ana	14-17[0_105]
14-2	2229-2231	of	abstract[105]	giv[105]	_	_
14-3	2232-2237	these	abstract[105]	giv[105]	_	_
14-4	2238-2248	approaches	abstract[105]	giv[105]	_	_
14-5	2249-2251	do	_	_	_	_
14-6	2252-2255	not	_	_	_	_
14-7	2256-2267	incorporate	_	_	_	_
14-8	2268-2271	the	abstract[106]	new[106]	_	_
14-9	2272-2281	influence	abstract[106]	new[106]	_	_
14-10	2282-2284	of	abstract[106]	new[106]	_	_
14-11	2285-2292	natural	abstract[106]|abstract[107]	new[106]|new[107]	appos	14-14[0_107]
14-12	2293-2306	stochasticity	abstract[106]|abstract[107]	new[106]|new[107]	_	_
14-13	2307-2308	(	_	_	_	_
14-14	2309-2319	randomness	abstract	giv	_	_
14-15	2320-2321	)	_	_	_	_
14-16	2322-2324	to	_	_	_	_
14-17	2325-2330	their	abstract|abstract[110]	giv|new[110]	ana	14-21
14-18	2331-2337	models	abstract[110]	new[110]	_	_
14-19	2338-2339	,	_	_	_	_
14-20	2340-2348	limiting	_	_	_	_
14-21	2349-2354	their	abstract|abstract[112]	giv|giv[112]	coref	15-5[118_0]
14-22	2355-2365	resolution	abstract[112]	giv[112]	_	_
14-23	2366-2379	predominantly	_	_	_	_
14-24	2380-2382	to	_	_	_	_
14-25	2383-2390	genomic	place[113]	new[113]	_	_
14-26	2391-2398	regions	place[113]	new[113]	_	_
14-27	2399-2403	with	place[113]	new[113]	_	_
14-28	2404-2407	the	place[113]|abstract[114]	new[113]|new[114]	coref	18-1[153_114]
14-29	2408-2415	highest	place[113]|abstract[114]	new[113]|new[114]	_	_
14-30	2416-2427	probability	place[113]|abstract[114]	new[113]|new[114]	_	_
14-31	2428-2430	of	place[113]|abstract[114]	new[113]|new[114]	_	_
14-32	2431-2437	having	place[113]|abstract[114]	new[113]|new[114]	_	_
14-33	2438-2447	undergone	place[113]|abstract[114]	new[113]|new[114]	_	_
14-34	2448-2449	a	place[113]|abstract[114]|event[116]	new[113]|new[114]|giv[116]	_	_
14-35	2450-2461	methylation	place[113]|abstract[114]|abstract|event[116]	new[113]|new[114]|giv|giv[116]	coref	16-4
14-36	2462-2468	change	place[113]|abstract[114]|event[116]	new[113]|new[114]|giv[116]	_	_
14-37	2469-2470	.	_	_	_	_

#Text=As a consequence , these approaches do not have the ability to distinguish the DMP signal associated with a specific treatment ( or disease ) from DMPs deriving from natural variation within control ( or heathy ) individuals , and are thus not suitable for clinical diagnostics .
15-1	2471-2473	As	_	_	_	_
15-2	2474-2475	a	abstract[117]	new[117]	_	_
15-3	2476-2487	consequence	abstract[117]	new[117]	_	_
15-4	2488-2489	,	_	_	_	_
15-5	2490-2495	these	abstract[118]	giv[118]	coref	17-26[150_118]
15-6	2496-2506	approaches	abstract[118]	giv[118]	_	_
15-7	2507-2509	do	_	_	_	_
15-8	2510-2513	not	_	_	_	_
15-9	2514-2518	have	_	_	_	_
15-10	2519-2522	the	abstract[119]	new[119]	_	_
15-11	2523-2530	ability	abstract[119]	new[119]	_	_
15-12	2531-2533	to	abstract[119]	new[119]	_	_
15-13	2534-2545	distinguish	abstract[119]	new[119]	_	_
15-14	2546-2549	the	abstract[119]|abstract[121]	new[119]|new[121]	coref	16-11[0_121]
15-15	2550-2553	DMP	abstract[119]|abstract|abstract[121]	new[119]|new|new[121]	coref	28-8[252_0]
15-16	2554-2560	signal	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-17	2561-2571	associated	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-18	2572-2576	with	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-19	2577-2578	a	abstract[119]|abstract[121]|abstract[122]	new[119]|new[121]|new[122]	coref	18-37[0_122]
15-20	2579-2587	specific	abstract[119]|abstract[121]|abstract[122]	new[119]|new[121]|new[122]	_	_
15-21	2588-2597	treatment	abstract[119]|abstract[121]|abstract[122]	new[119]|new[121]|new[122]	_	_
15-22	2598-2599	(	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-23	2600-2602	or	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-24	2603-2610	disease	abstract[119]|abstract[121]|abstract	new[119]|new[121]|giv	_	_
15-25	2611-2612	)	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-26	2613-2617	from	abstract[119]	new[119]	_	_
15-27	2618-2622	DMPs	abstract[119]|abstract[124]	new[119]|giv[124]	coref	21-10[0_124]
15-28	2623-2631	deriving	abstract[119]|abstract[124]	new[119]|giv[124]	_	_
15-29	2632-2636	from	abstract[119]|abstract[124]	new[119]|giv[124]	_	_
15-30	2637-2644	natural	abstract[119]|abstract[124]|abstract[125]	new[119]|giv[124]|new[125]	coref	16-4[131_125]
15-31	2645-2654	variation	abstract[119]|abstract[124]|abstract[125]	new[119]|giv[124]|new[125]	_	_
15-32	2655-2661	within	abstract[119]|abstract[124]|abstract[125]	new[119]|giv[124]|new[125]	_	_
15-33	2662-2669	control	abstract[119]|abstract[124]|abstract[125]|person|animal[127]	new[119]|giv[124]|new[125]|new|new[127]	coref	16-23[138_127]
15-34	2670-2671	(	abstract[119]|abstract[124]|abstract[125]|animal[127]	new[119]|giv[124]|new[125]|new[127]	_	_
15-35	2672-2674	or	abstract[119]|abstract[124]|abstract[125]|animal[127]	new[119]|giv[124]|new[125]|new[127]	_	_
15-36	2675-2681	heathy	abstract[119]|abstract[124]|abstract[125]|animal[127]	new[119]|giv[124]|new[125]|new[127]	_	_
15-37	2682-2683	)	abstract[119]|abstract[124]|abstract[125]|animal[127]	new[119]|giv[124]|new[125]|new[127]	_	_
15-38	2684-2695	individuals	abstract[119]|abstract[124]|abstract[125]|animal[127]	new[119]|giv[124]|new[125]|new[127]	_	_
15-39	2696-2697	,	_	_	_	_
15-40	2698-2701	and	_	_	_	_
15-41	2702-2705	are	_	_	_	_
15-42	2706-2710	thus	_	_	_	_
15-43	2711-2714	not	_	_	_	_
15-44	2715-2723	suitable	_	_	_	_
15-45	2724-2727	for	_	_	_	_
15-46	2728-2736	clinical	abstract[128]	new[128]	coref	16-7[0_128]
15-47	2737-2748	diagnostics	abstract[128]	new[128]	_	_
15-48	2749-2750	.	_	_	_	_

#Text=We suggest that methylation variation in diagnostics is essentially a signal detection problem , equivalent to a binary classification problem for discriminating healthy versus diseased individuals .
16-1	2751-2753	We	person	acc	ana	28-1
16-2	2754-2761	suggest	_	_	_	_
16-3	2762-2766	that	_	_	_	_
16-4	2767-2778	methylation	abstract|abstract[131]	giv|giv[131]	coref|coref	16-9[135_131]|18-5
16-5	2779-2788	variation	abstract[131]	giv[131]	_	_
16-6	2789-2791	in	abstract[131]	giv[131]	_	_
16-7	2792-2803	diagnostics	abstract[131]|abstract	giv[131]|giv	coref	23-17[202_0]
16-8	2804-2806	is	_	_	_	_
16-9	2807-2818	essentially	abstract[135]	giv[135]	coref	18-31[166_135]
16-10	2819-2820	a	abstract[135]	giv[135]	_	_
16-11	2821-2827	signal	abstract|abstract[134]|abstract[135]	giv|new[134]|giv[135]	coref|coref	17-1[140_134]|18-35[168_0]
16-12	2828-2837	detection	abstract[134]|abstract[135]	new[134]|giv[135]	_	_
16-13	2838-2845	problem	abstract[135]	giv[135]	_	_
16-14	2846-2847	,	abstract[135]	giv[135]	_	_
16-15	2848-2858	equivalent	abstract[135]	giv[135]	_	_
16-16	2859-2861	to	abstract[135]	giv[135]	_	_
16-17	2862-2863	a	abstract[135]|abstract[137]	giv[135]|new[137]	coref	17-10[144_137]
16-18	2864-2870	binary	abstract[135]|abstract[137]	giv[135]|new[137]	_	_
16-19	2871-2885	classification	abstract[135]|abstract|abstract[137]	giv[135]|new|new[137]	ana	17-18
16-20	2886-2893	problem	abstract[135]|abstract[137]	giv[135]|new[137]	_	_
16-21	2894-2897	for	abstract[135]|abstract[137]	giv[135]|new[137]	_	_
16-22	2898-2912	discriminating	abstract[135]|abstract[137]	giv[135]|new[137]	_	_
16-23	2913-2920	healthy	abstract[135]|abstract[137]|animal[138]	giv[135]|new[137]|giv[138]	_	_
16-24	2921-2927	versus	abstract[135]|abstract[137]|animal[138]	giv[135]|new[137]|giv[138]	_	_
16-25	2928-2936	diseased	abstract[135]|abstract[137]|animal[138]	giv[135]|new[137]|giv[138]	_	_
16-26	2937-2948	individuals	abstract[135]|abstract[137]|animal[138]	giv[135]|new[137]|giv[138]	_	_
16-27	2949-2950	.	_	_	_	_

#Text=Signal detection theory provides the methodological framework to address this type of detection problem , evidenced in its common application to clinical diagnostic tests , machine-learning ( ML ) approaches , and human communication technologies .
17-1	2951-2957	Signal	person|abstract[140]|abstract[141]	new|giv[140]|new[141]	coref|coref	17-13[0_140]|30-10[272_141]
17-2	2958-2967	detection	abstract[140]|abstract[141]	giv[140]|new[141]	_	_
17-3	2968-2974	theory	abstract[141]	new[141]	_	_
17-4	2975-2983	provides	_	_	_	_
17-5	2984-2987	the	abstract[142]	new[142]	_	_
17-6	2988-3002	methodological	abstract[142]	new[142]	_	_
17-7	3003-3012	framework	abstract[142]	new[142]	_	_
17-8	3013-3015	to	abstract[142]	new[142]	_	_
17-9	3016-3023	address	abstract[142]	new[142]	_	_
17-10	3024-3028	this	abstract[142]|abstract[144]	new[142]|giv[144]	_	_
17-11	3029-3033	type	abstract[142]|abstract[144]	new[142]|giv[144]	_	_
17-12	3034-3036	of	abstract[142]|abstract[144]	new[142]|giv[144]	_	_
17-13	3037-3046	detection	abstract[142]|abstract|abstract[144]	new[142]|giv|giv[144]	coref	25-1
17-14	3047-3054	problem	abstract[142]|abstract[144]	new[142]|giv[144]	_	_
17-15	3055-3056	,	abstract[142]	new[142]	_	_
17-16	3057-3066	evidenced	abstract[142]	new[142]	_	_
17-17	3067-3069	in	abstract[142]	new[142]	_	_
17-18	3070-3073	its	abstract[142]|abstract|abstract[146]	new[142]|giv|giv[146]	coref	25-14
17-19	3074-3080	common	abstract[142]|abstract[146]	new[142]|giv[146]	_	_
17-20	3081-3092	application	abstract[142]|abstract[146]	new[142]|giv[146]	_	_
17-21	3093-3095	to	abstract[142]|abstract[146]	new[142]|giv[146]	_	_
17-22	3096-3104	clinical	abstract[142]|abstract[146]|abstract[147]	new[142]|giv[146]|new[147]	coref	24-26[212_147]
17-23	3105-3115	diagnostic	abstract[142]|abstract[146]|abstract[147]	new[142]|giv[146]|new[147]	_	_
17-24	3116-3121	tests	abstract[142]|abstract[146]|abstract[147]	new[142]|giv[146]|new[147]	_	_
17-25	3122-3123	,	abstract[142]|abstract[146]	new[142]|giv[146]	_	_
17-26	3124-3140	machine-learning	abstract[142]|abstract[146]|abstract|abstract[150]	new[142]|giv[146]|new|giv[150]	coref	24-7[207_150]
17-27	3141-3142	(	abstract[142]|abstract[146]|abstract[150]	new[142]|giv[146]|giv[150]	_	_
17-28	3143-3145	ML	abstract[142]|abstract[146]|abstract|abstract[150]	new[142]|giv[146]|new|giv[150]	coref	30-14
17-29	3146-3147	)	abstract[142]|abstract[146]|abstract[150]	new[142]|giv[146]|giv[150]	_	_
17-30	3148-3158	approaches	abstract[142]|abstract[146]|abstract[150]	new[142]|giv[146]|giv[150]	_	_
17-31	3159-3160	,	abstract[142]|abstract[146]	new[142]|giv[146]	_	_
17-32	3161-3164	and	abstract[142]|abstract[146]	new[142]|giv[146]	_	_
17-33	3165-3170	human	abstract[142]|abstract[146]|abstract[151]|abstract[152]	new[142]|giv[146]|new[151]|new[152]	_	_
17-34	3171-3184	communication	abstract[142]|abstract[146]|abstract[151]|abstract[152]	new[142]|giv[146]|new[151]|new[152]	_	_
17-35	3185-3197	technologies	abstract[142]|abstract[146]|abstract[152]	new[142]|giv[146]|new[152]	_	_
17-36	3198-3199	.	_	_	_	_

#Text=The probability of extreme methylation changes occurring spontaneously in a control group of samples by the stochastic fluctuations inherent to biochemical processes and DNA maintenance , requires the discrimination of this background variation from a biological treatment signal .
18-1	3200-3203	The	abstract[153]	giv[153]	coref	19-16[173_153]
18-2	3204-3215	probability	abstract[153]	giv[153]	_	_
18-3	3216-3218	of	abstract[153]	giv[153]	_	_
18-4	3219-3226	extreme	abstract[153]|abstract[155]	giv[153]|giv[155]	coref	19-6[171_155]
18-5	3227-3238	methylation	abstract[153]|abstract|abstract[155]	giv[153]|giv|giv[155]	coref	19-8
18-6	3239-3246	changes	abstract[153]|abstract[155]	giv[153]|giv[155]	_	_
18-7	3247-3256	occurring	abstract[153]|abstract[155]	giv[153]|giv[155]	_	_
18-8	3257-3270	spontaneously	abstract[153]|abstract[155]	giv[153]|giv[155]	_	_
18-9	3271-3273	in	abstract[153]|abstract[155]	giv[153]|giv[155]	_	_
18-10	3274-3275	a	abstract[153]|abstract[155]|animal[157]	giv[153]|giv[155]|new[157]	coref	21-26[187_157]
18-11	3276-3283	control	abstract[153]|abstract[155]|abstract|animal[157]	giv[153]|giv[155]|new|new[157]	coref	28-19
18-12	3284-3289	group	abstract[153]|abstract[155]|animal[157]	giv[153]|giv[155]|new[157]	_	_
18-13	3290-3292	of	abstract[153]|abstract[155]|animal[157]	giv[153]|giv[155]|new[157]	_	_
18-14	3293-3300	samples	abstract[153]|abstract[155]|animal[157]|object	giv[153]|giv[155]|new[157]|giv	_	_
18-15	3301-3303	by	abstract[153]|abstract[155]	giv[153]|giv[155]	_	_
18-16	3304-3307	the	abstract[153]|abstract[155]|abstract[159]	giv[153]|giv[155]|new[159]	coref	20-1[176_159]
18-17	3308-3318	stochastic	abstract[153]|abstract[155]|abstract[159]	giv[153]|giv[155]|new[159]	_	_
18-18	3319-3331	fluctuations	abstract[153]|abstract[155]|abstract[159]	giv[153]|giv[155]|new[159]	_	_
18-19	3332-3340	inherent	abstract[153]|abstract[155]|abstract[159]	giv[153]|giv[155]|new[159]	_	_
18-20	3341-3343	to	_	_	_	_
18-21	3344-3355	biochemical	abstract[160]|abstract[161]	giv[160]|giv[161]	coref|coref	18-21[161_160]|20-7[177_161]
18-22	3356-3365	processes	abstract[160]|abstract[161]	giv[160]|giv[161]	_	_
18-23	3366-3369	and	abstract[161]	giv[161]	_	_
18-24	3370-3373	DNA	abstract[161]|abstract|abstract[163]	giv[161]|giv|new[163]	coref	27-6
18-25	3374-3385	maintenance	abstract[161]|abstract[163]	giv[161]|new[163]	_	_
18-26	3386-3387	,	_	_	_	_
18-27	3388-3396	requires	_	_	_	_
18-28	3397-3400	the	abstract[164]	new[164]	_	_
18-29	3401-3415	discrimination	abstract[164]	new[164]	_	_
18-30	3416-3418	of	abstract[164]	new[164]	_	_
18-31	3419-3423	this	abstract[164]|abstract[166]	new[164]|giv[166]	coref	20-12[179_166]
18-32	3424-3434	background	abstract[164]|abstract|abstract[166]	new[164]|new|giv[166]	coref	20-13
18-33	3435-3444	variation	abstract[164]|abstract[166]	new[164]|giv[166]	_	_
18-34	3445-3449	from	abstract[164]	new[164]	_	_
18-35	3450-3451	a	abstract[164]|abstract[168]	new[164]|giv[168]	coref	24-7[0_168]
18-36	3452-3462	biological	abstract[164]|abstract[168]	new[164]|giv[168]	_	_
18-37	3463-3472	treatment	abstract[164]|abstract|abstract[168]	new[164]|giv|giv[168]	coref	29-34
18-38	3473-3479	signal	abstract[164]|abstract[168]	new[164]|giv[168]	_	_
18-39	3480-3481	.	_	_	_	_

#Text=Regardless of environmental constancy , statistically significant methylation changes are found in control populations with probability greater than zero .
19-1	3482-3492	Regardless	_	_	_	_
19-2	3493-3495	of	_	_	_	_
19-3	3496-3509	environmental	abstract[169]	new[169]	_	_
19-4	3510-3519	constancy	abstract[169]	new[169]	_	_
19-5	3520-3521	,	_	_	_	_
19-6	3522-3535	statistically	abstract[171]	giv[171]	coref	29-16[262_171]
19-7	3536-3547	significant	abstract[171]	giv[171]	_	_
19-8	3548-3559	methylation	abstract|abstract[171]	giv|giv[171]	coref	21-20
19-9	3560-3567	changes	abstract[171]	giv[171]	_	_
19-10	3568-3571	are	_	_	_	_
19-11	3572-3577	found	_	_	_	_
19-12	3578-3580	in	_	_	_	_
19-13	3581-3588	control	person[172]	giv[172]	coref	21-14[184_172]
19-14	3589-3600	populations	person[172]	giv[172]	_	_
19-15	3601-3605	with	person[172]	giv[172]	_	_
19-16	3606-3617	probability	person[172]|abstract[173]	giv[172]|giv[173]	coref	28-25[257_173]
19-17	3618-3625	greater	person[172]|abstract[173]	giv[172]|giv[173]	_	_
19-18	3626-3630	than	_	_	_	_
19-19	3631-3635	zero	abstract	new	ana	21-4
19-20	3636-3637	.	_	_	_	_

#Text=These system fluctuations , inherent in biological stochastic processes , comprise natural background variation detected in human methylomes .
20-1	3638-3643	These	abstract[176]	giv[176]	coref	22-22[194_176]
20-2	3644-3650	system	abstract|abstract[176]	new|giv[176]	_	_
20-3	3651-3663	fluctuations	abstract[176]	giv[176]	_	_
20-4	3664-3665	,	abstract[176]	giv[176]	_	_
20-5	3666-3674	inherent	abstract[176]	giv[176]	_	_
20-6	3675-3677	in	_	_	_	_
20-7	3678-3688	biological	abstract[177]	giv[177]	_	_
20-8	3689-3699	stochastic	abstract[177]	giv[177]	_	_
20-9	3700-3709	processes	abstract[177]	giv[177]	_	_
20-10	3710-3711	,	_	_	_	_
20-11	3712-3720	comprise	_	_	_	_
20-12	3721-3728	natural	abstract[179]	giv[179]	coref	23-1[198_179]
20-13	3729-3739	background	abstract|abstract[179]	giv|giv[179]	coref	27-19
20-14	3740-3749	variation	abstract[179]	giv[179]	_	_
20-15	3750-3758	detected	abstract[179]	giv[179]	_	_
20-16	3759-3761	in	abstract[179]	giv[179]	_	_
20-17	3762-3767	human	abstract[179]|substance[180]	giv[179]|new[180]	_	_
20-18	3768-3778	methylomes	abstract[179]|substance[180]	giv[179]|new[180]	_	_
20-19	3779-3780	.	_	_	_	_

#Text=By simulation , it is feasible to demonstrate that DMPs spontaneously arise in control populations , and that regulatory methylation signals also occur naturally in the control group .
21-1	3781-3783	By	_	_	_	_
21-2	3784-3794	simulation	abstract	new	coref	31-15
21-3	3795-3796	,	_	_	_	_
21-4	3797-3799	it	abstract	giv	_	_
21-5	3800-3802	is	_	_	_	_
21-6	3803-3811	feasible	_	_	_	_
21-7	3812-3814	to	_	_	_	_
21-8	3815-3826	demonstrate	_	_	_	_
21-9	3827-3831	that	_	_	_	_
21-10	3832-3836	DMPs	abstract	giv	coref	29-11
21-11	3837-3850	spontaneously	_	_	_	_
21-12	3851-3856	arise	_	_	_	_
21-13	3857-3859	in	_	_	_	_
21-14	3860-3867	control	person[184]	giv[184]	coref	27-9[244_184]
21-15	3868-3879	populations	person[184]	giv[184]	_	_
21-16	3880-3881	,	_	_	_	_
21-17	3882-3885	and	_	_	_	_
21-18	3886-3890	that	_	_	_	_
21-19	3891-3901	regulatory	abstract[186]	new[186]	_	_
21-20	3902-3913	methylation	abstract|abstract[186]	giv|new[186]	coref	22-5
21-21	3914-3921	signals	abstract[186]	new[186]	_	_
21-22	3922-3926	also	_	_	_	_
21-23	3927-3932	occur	_	_	_	_
21-24	3933-3942	naturally	_	_	_	_
21-25	3943-3945	in	_	_	_	_
21-26	3946-3949	the	animal[187]	giv[187]	coref	29-32[266_187]
21-27	3950-3957	control	animal[187]	giv[187]	_	_
21-28	3958-3963	group	animal[187]	giv[187]	_	_
21-29	3964-3965	.	_	_	_	_

#Text=Stochastic fluctuation of the methylation process is expected , since methylation regulatory machinery participates , not only in organismal adaptation to micro- and macro-environmental fluctuations , but also in transitions across different stages of organismal ontogenetic development .
22-1	3966-3976	Stochastic	abstract[188]	new[188]	_	_
22-2	3977-3988	fluctuation	abstract[188]	new[188]	_	_
22-3	3989-3991	of	abstract[188]	new[188]	_	_
22-4	3992-3995	the	abstract[188]|abstract[190]	new[188]|new[190]	_	_
22-5	3996-4007	methylation	abstract[188]|abstract|abstract[190]	new[188]|giv|new[190]	coref	22-11
22-6	4008-4015	process	abstract[188]|abstract[190]	new[188]|new[190]	_	_
22-7	4016-4018	is	_	_	_	_
22-8	4019-4027	expected	_	_	_	_
22-9	4028-4029	,	_	_	_	_
22-10	4030-4035	since	_	_	_	_
22-11	4036-4047	methylation	abstract|abstract[192]	giv|new[192]	coref	23-11
22-12	4048-4058	regulatory	abstract[192]	new[192]	_	_
22-13	4059-4068	machinery	abstract[192]	new[192]	_	_
22-14	4069-4081	participates	_	_	_	_
22-15	4082-4083	,	_	_	_	_
22-16	4084-4087	not	_	_	_	_
22-17	4088-4092	only	abstract[193]	new[193]	_	_
22-18	4093-4095	in	abstract[193]	new[193]	_	_
22-19	4096-4106	organismal	abstract[193]	new[193]	_	_
22-20	4107-4117	adaptation	abstract[193]	new[193]	_	_
22-21	4118-4120	to	abstract[193]	new[193]	_	_
22-22	4121-4127	micro-	abstract[193]|abstract[194]	new[193]|giv[194]	_	_
22-23	4128-4131	and	abstract[193]|abstract[194]	new[193]|giv[194]	_	_
22-24	4132-4151	macro-environmental	abstract[193]|abstract[194]	new[193]|giv[194]	_	_
22-25	4152-4164	fluctuations	abstract[193]|abstract[194]	new[193]|giv[194]	_	_
22-26	4165-4166	,	_	_	_	_
22-27	4167-4170	but	_	_	_	_
22-28	4171-4175	also	_	_	_	_
22-29	4176-4178	in	_	_	_	_
22-30	4179-4190	transitions	event[195]	new[195]	_	_
22-31	4191-4197	across	event[195]	new[195]	_	_
22-32	4198-4207	different	event[195]|abstract[196]	new[195]|new[196]	_	_
22-33	4208-4214	stages	event[195]|abstract[196]	new[195]|new[196]	_	_
22-34	4215-4217	of	event[195]|abstract[196]	new[195]|new[196]	_	_
22-35	4218-4228	organismal	event[195]|abstract[196]|event[197]	new[195]|new[196]|giv[197]	_	_
22-36	4229-4240	ontogenetic	event[195]|abstract[196]|event[197]	new[195]|new[196]|giv[197]	_	_
22-37	4241-4252	development	event[195]|abstract[196]|event[197]	new[195]|new[196]|giv[197]	_	_
22-38	4253-4254	.	_	_	_	_

#Text=This variation must be factored into the construction of a methylation pipeline to be used in clinical diagnostics .
23-1	4255-4259	This	abstract[198]	giv[198]	coref	27-1[241_198]
23-2	4260-4269	variation	abstract[198]	giv[198]	_	_
23-3	4270-4274	must	_	_	_	_
23-4	4275-4277	be	_	_	_	_
23-5	4278-4286	factored	_	_	_	_
23-6	4287-4291	into	_	_	_	_
23-7	4292-4295	the	abstract[199]	new[199]	_	_
23-8	4296-4308	construction	abstract[199]	new[199]	_	_
23-9	4309-4311	of	abstract[199]	new[199]	_	_
23-10	4312-4313	a	abstract[199]|object[201]	new[199]|new[201]	_	_
23-11	4314-4325	methylation	abstract[199]|abstract|object[201]	new[199]|giv|new[201]	coref	27-6[243_0]
23-12	4326-4334	pipeline	abstract[199]|object[201]	new[199]|new[201]	_	_
23-13	4335-4337	to	abstract[199]|object[201]	new[199]|new[201]	_	_
23-14	4338-4340	be	abstract[199]|object[201]	new[199]|new[201]	_	_
23-15	4341-4345	used	abstract[199]|object[201]	new[199]|new[201]	_	_
23-16	4346-4348	in	abstract[199]|object[201]	new[199]|new[201]	_	_
23-17	4349-4357	clinical	abstract[199]|object[201]|abstract[202]	new[199]|new[201]|giv[202]	coref	24-11[0_202]
23-18	4358-4369	diagnostics	abstract[199]|object[201]|abstract[202]	new[199]|new[201]|giv[202]	_	_
23-19	4370-4371	.	_	_	_	_

#Text=The need for the application of signal detection-based approaches in diagnostics was pointed out decades ago , and is standard practice in current implementations of clinical diagnostic tests .
24-1	4372-4375	The	abstract[203]	new[203]	_	_
24-2	4376-4380	need	abstract[203]	new[203]	_	_
24-3	4381-4384	for	abstract[203]	new[203]	_	_
24-4	4385-4388	the	abstract[203]|abstract[204]	new[203]|new[204]	_	_
24-5	4389-4400	application	abstract[203]|abstract[204]	new[203]|new[204]	_	_
24-6	4401-4403	of	abstract[203]|abstract[204]	new[203]|new[204]	_	_
24-7	4404-4410	signal	abstract[203]|abstract[204]|abstract|abstract[207]	new[203]|new[204]|giv|giv[207]	coref|coref	25-1[214_207]|26-15
24-8	4411-4426	detection-based	abstract[203]|abstract[204]|abstract|abstract[207]	new[203]|new[204]|new|giv[207]	_	_
24-9	4427-4437	approaches	abstract[203]|abstract[204]|abstract[207]	new[203]|new[204]|giv[207]	_	_
24-10	4438-4440	in	abstract[203]|abstract[204]	new[203]|new[204]	_	_
24-11	4441-4452	diagnostics	abstract[203]|abstract[204]|abstract	new[203]|new[204]|giv	coref	31-10[278_0]
24-12	4453-4456	was	_	_	_	_
24-13	4457-4464	pointed	_	_	_	_
24-14	4465-4468	out	_	_	_	_
24-15	4469-4476	decades	time[209]	new[209]	_	_
24-16	4477-4480	ago	time[209]	new[209]	_	_
24-17	4481-4482	,	_	_	_	_
24-18	4483-4486	and	_	_	_	_
24-19	4487-4489	is	_	_	_	_
24-20	4490-4498	standard	abstract[210]	new[210]	_	_
24-21	4499-4507	practice	abstract[210]	new[210]	_	_
24-22	4508-4510	in	abstract[210]	new[210]	_	_
24-23	4511-4518	current	abstract[210]|abstract[211]	new[210]|new[211]	coref	25-10[216_211]
24-24	4519-4534	implementations	abstract[210]|abstract[211]	new[210]|new[211]	_	_
24-25	4535-4537	of	abstract[210]|abstract[211]	new[210]|new[211]	_	_
24-26	4538-4546	clinical	abstract[210]|abstract[211]|abstract[212]	new[210]|new[211]|giv[212]	coref	31-18[282_212]
24-27	4547-4557	diagnostic	abstract[210]|abstract[211]|abstract[212]	new[210]|new[211]|giv[212]	_	_
24-28	4558-4563	tests	abstract[210]|abstract[211]|abstract[212]	new[210]|new[211]|giv[212]	_	_
24-29	4564-4565	.	_	_	_	_

#Text=Detection approaches are , by default , included in machine/statistical learning implementations for classification tasks , since the evaluation of classifier performance is basically a detection problem .
25-1	4566-4575	Detection	abstract|abstract[214]	giv|giv[214]	coref	25-26
25-2	4576-4586	approaches	abstract[214]	giv[214]	_	_
25-3	4587-4590	are	_	_	_	_
25-4	4591-4592	,	_	_	_	_
25-5	4593-4595	by	_	_	_	_
25-6	4596-4603	default	_	_	_	_
25-7	4604-4605	,	_	_	_	_
25-8	4606-4614	included	_	_	_	_
25-9	4615-4617	in	_	_	_	_
25-10	4618-4637	machine/statistical	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
25-11	4638-4646	learning	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
25-12	4647-4662	implementations	abstract[216]	giv[216]	_	_
25-13	4663-4666	for	_	_	_	_
25-14	4667-4681	classification	abstract|abstract[218]	giv|new[218]	coref	26-46
25-15	4682-4687	tasks	abstract[218]	new[218]	_	_
25-16	4688-4689	,	_	_	_	_
25-17	4690-4695	since	_	_	_	_
25-18	4696-4699	the	abstract[219]	new[219]	coref	25-24[223_219]
25-19	4700-4710	evaluation	abstract[219]	new[219]	_	_
25-20	4711-4713	of	abstract[219]	new[219]	_	_
25-21	4714-4724	classifier	abstract[219]|object|abstract[221]	new[219]|new|new[221]	_	_
25-22	4725-4736	performance	abstract[219]|abstract[221]	new[219]|new[221]	_	_
25-23	4737-4739	is	_	_	_	_
25-24	4740-4749	basically	abstract[223]	giv[223]	coref	26-45[238_223]
25-25	4750-4751	a	abstract[223]	giv[223]	_	_
25-26	4752-4761	detection	abstract|abstract[223]	giv|giv[223]	coref	26-53[240_0]
25-27	4762-4769	problem	abstract[223]	giv[223]	_	_
25-28	4770-4771	.	_	_	_	_

#Text=Thus , the determination of the optimal cutoff ( threshold ) value at which signal can be discriminated from noise at an acceptable signal-to-noise ratio ( i.e. , maximum accuracy and sensitivity , lowest false discovery rate ( FDR ) ) is equivalent to a classification problem , a direct corollary to diagnostic detection .
26-1	4772-4776	Thus	_	_	_	_
26-2	4777-4778	,	_	_	_	_
26-3	4779-4782	the	abstract[224]	new[224]	_	_
26-4	4783-4796	determination	abstract[224]	new[224]	_	_
26-5	4797-4799	of	abstract[224]	new[224]	_	_
26-6	4800-4803	the	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-7	4804-4811	optimal	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-8	4812-4818	cutoff	abstract[224]|abstract|abstract[227]	new[224]|new|giv[227]	appos	26-10
26-9	4819-4820	(	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-10	4821-4830	threshold	abstract[224]|abstract|abstract[227]	new[224]|giv|giv[227]	_	_
26-11	4831-4832	)	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-12	4833-4838	value	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-13	4839-4841	at	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-14	4842-4847	which	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-15	4848-4854	signal	abstract[224]|abstract[227]|abstract	new[224]|giv[227]|giv	coref	27-15[247_0]
26-16	4855-4858	can	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-17	4859-4861	be	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-18	4862-4875	discriminated	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-19	4876-4880	from	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-20	4881-4886	noise	abstract[224]|abstract[227]|abstract	new[224]|giv[227]|new	_	_
26-21	4887-4889	at	abstract[224]|abstract[227]	new[224]|giv[227]	_	_
26-22	4890-4892	an	abstract[224]|abstract[227]|abstract[231]	new[224]|giv[227]|new[231]	_	_
26-23	4893-4903	acceptable	abstract[224]|abstract[227]|abstract[231]	new[224]|giv[227]|new[231]	_	_
26-24	4904-4919	signal-to-noise	abstract[224]|abstract[227]|abstract|abstract[231]	new[224]|giv[227]|new|new[231]	_	_
26-25	4920-4925	ratio	abstract[224]|abstract[227]|abstract[231]	new[224]|giv[227]|new[231]	_	_
26-26	4926-4927	(	_	_	_	_
26-27	4928-4932	i.e.	abstract[232]	new[232]	_	_
26-28	4933-4934	,	abstract[232]	new[232]	_	_
26-29	4935-4942	maximum	abstract[232]	new[232]	_	_
26-30	4943-4951	accuracy	abstract[232]	new[232]	_	_
26-31	4952-4955	and	_	_	_	_
26-32	4956-4967	sensitivity	abstract	new	_	_
26-33	4968-4969	,	_	_	_	_
26-34	4970-4976	lowest	abstract[235]	new[235]	appos	26-39[0_235]
26-35	4977-4982	false	abstract[235]	new[235]	_	_
26-36	4983-4992	discovery	abstract|abstract[235]	new|new[235]	_	_
26-37	4993-4997	rate	abstract[235]	new[235]	_	_
26-38	4998-4999	(	_	_	_	_
26-39	5000-5003	FDR	abstract	giv	_	_
26-40	5004-5005	)	_	_	_	_
26-41	5006-5007	)	_	_	_	_
26-42	5008-5010	is	_	_	_	_
26-43	5011-5021	equivalent	_	_	_	_
26-44	5022-5024	to	_	_	_	_
26-45	5025-5026	a	abstract[238]	giv[238]	appos	26-49[239_238]
26-46	5027-5041	classification	abstract|abstract[238]	giv|giv[238]	_	_
26-47	5042-5049	problem	abstract[238]	giv[238]	_	_
26-48	5050-5051	,	_	_	_	_
26-49	5052-5053	a	abstract[239]	giv[239]	coref	30-4[268_239]
26-50	5054-5060	direct	abstract[239]	giv[239]	_	_
26-51	5061-5070	corollary	abstract[239]	giv[239]	_	_
26-52	5071-5073	to	abstract[239]	giv[239]	_	_
26-53	5074-5084	diagnostic	abstract[239]|abstract[240]	giv[239]|giv[240]	coref	30-10[271_240]
26-54	5085-5094	detection	abstract[239]|abstract[240]	giv[239]|giv[240]	_	_
26-55	5095-5096	.	_	_	_	_

#Text=The natural spontaneous variation of DNA methylation in human populations complicates the discrimination of the methylation signal from background variation .
27-1	5097-5100	The	abstract[241]	giv[241]	coref	27-19[249_241]
27-2	5101-5108	natural	abstract[241]	giv[241]	_	_
27-3	5109-5120	spontaneous	abstract[241]	giv[241]	_	_
27-4	5121-5130	variation	abstract[241]	giv[241]	_	_
27-5	5131-5133	of	abstract[241]	giv[241]	_	_
27-6	5134-5137	DNA	abstract[241]|abstract|abstract[243]	giv[241]|giv|giv[243]	coref	27-16[0_243]
27-7	5138-5149	methylation	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
27-8	5150-5152	in	abstract[241]	giv[241]	_	_
27-9	5153-5158	human	abstract[241]|person[244]	giv[241]|giv[244]	_	_
27-10	5159-5170	populations	abstract[241]|person[244]	giv[241]|giv[244]	_	_
27-11	5171-5182	complicates	_	_	_	_
27-12	5183-5186	the	abstract[245]	new[245]	_	_
27-13	5187-5201	discrimination	abstract[245]	new[245]	_	_
27-14	5202-5204	of	abstract[245]	new[245]	_	_
27-15	5205-5208	the	abstract[245]|abstract[247]	new[245]|giv[247]	coref	30-10[0_247]
27-16	5209-5220	methylation	abstract[245]|abstract|abstract[247]	new[245]|giv|giv[247]	_	_
27-17	5221-5227	signal	abstract[245]|abstract[247]	new[245]|giv[247]	_	_
27-18	5228-5232	from	abstract[245]	new[245]	_	_
27-19	5233-5243	background	abstract[245]|abstract|abstract[249]	new[245]|giv|giv[249]	_	_
27-20	5244-5253	variation	abstract[245]|abstract[249]	new[245]|giv[249]	_	_
27-21	5254-5255	.	_	_	_	_

#Text=We address this issue by determining whether a given DMP detected in the treatment/patient population occurs within the control population as well , and the probability of observing it .
28-1	5256-5258	We	person	giv	ana	30-2
28-2	5259-5266	address	_	_	_	_
28-3	5267-5271	this	abstract[251]	new[251]	_	_
28-4	5272-5277	issue	abstract[251]	new[251]	_	_
28-5	5278-5280	by	_	_	_	_
28-6	5281-5292	determining	_	_	_	_
28-7	5293-5300	whether	_	_	_	_
28-8	5301-5302	a	abstract[252]	giv[252]	_	_
28-9	5303-5308	given	abstract[252]	giv[252]	_	_
28-10	5309-5312	DMP	abstract[252]	giv[252]	_	_
28-11	5313-5321	detected	abstract[252]	giv[252]	_	_
28-12	5322-5324	in	abstract[252]	giv[252]	_	_
28-13	5325-5328	the	abstract[252]|person[254]	giv[252]|new[254]	coref	28-18[256_254]
28-14	5329-5346	treatment/patient	abstract[252]|place|person[254]	giv[252]|new|new[254]	_	_
28-15	5347-5357	population	abstract[252]|person[254]	giv[252]|new[254]	_	_
28-16	5358-5364	occurs	_	_	_	_
28-17	5365-5371	within	_	_	_	_
28-18	5372-5375	the	person[256]	giv[256]	_	_
28-19	5376-5383	control	abstract|person[256]	giv|giv[256]	_	_
28-20	5384-5394	population	person[256]	giv[256]	_	_
28-21	5395-5397	as	_	_	_	_
28-22	5398-5402	well	_	_	_	_
28-23	5403-5404	,	_	_	_	_
28-24	5405-5408	and	_	_	_	_
28-25	5409-5412	the	abstract[257]	giv[257]	ana	28-29[0_257]
28-26	5413-5424	probability	abstract[257]	giv[257]	_	_
28-27	5425-5427	of	abstract[257]	giv[257]	_	_
28-28	5428-5437	observing	abstract[257]	giv[257]	_	_
28-29	5438-5440	it	abstract[257]|abstract	giv[257]|giv	coref	29-22[263_0]
28-30	5441-5442	.	_	_	_	_

#Text=Therefore , the focus is not on the identification of DMPs , but on whether these statistically significant changes occur with high probability ( under the fixed experimental conditions ) in only the treatment group .
29-1	5443-5452	Therefore	_	_	_	_
29-2	5453-5454	,	_	_	_	_
29-3	5455-5458	the	abstract[259]	new[259]	_	_
29-4	5459-5464	focus	abstract[259]	new[259]	_	_
29-5	5465-5467	is	_	_	_	_
29-6	5468-5471	not	_	_	_	_
29-7	5472-5474	on	_	_	_	_
29-8	5475-5478	the	abstract[260]	new[260]	_	_
29-9	5479-5493	identification	abstract[260]	new[260]	_	_
29-10	5494-5496	of	abstract[260]	new[260]	_	_
29-11	5497-5501	DMPs	abstract[260]|abstract	new[260]|giv	_	_
29-12	5502-5503	,	_	_	_	_
29-13	5504-5507	but	_	_	_	_
29-14	5508-5510	on	_	_	_	_
29-15	5511-5518	whether	_	_	_	_
29-16	5519-5524	these	abstract[262]	giv[262]	_	_
29-17	5525-5538	statistically	abstract[262]	giv[262]	_	_
29-18	5539-5550	significant	abstract[262]	giv[262]	_	_
29-19	5551-5558	changes	abstract[262]	giv[262]	_	_
29-20	5559-5564	occur	_	_	_	_
29-21	5565-5569	with	_	_	_	_
29-22	5570-5574	high	abstract[263]	giv[263]	_	_
29-23	5575-5586	probability	abstract[263]	giv[263]	_	_
29-24	5587-5588	(	_	_	_	_
29-25	5589-5594	under	_	_	_	_
29-26	5595-5598	the	abstract[264]	new[264]	_	_
29-27	5599-5604	fixed	abstract[264]	new[264]	_	_
29-28	5605-5617	experimental	abstract[264]	new[264]	_	_
29-29	5618-5628	conditions	abstract[264]	new[264]	_	_
29-30	5629-5630	)	_	_	_	_
29-31	5631-5633	in	_	_	_	_
29-32	5634-5638	only	animal[266]	giv[266]	_	_
29-33	5639-5642	the	animal[266]	giv[266]	_	_
29-34	5643-5652	treatment	abstract|animal[266]	giv|giv[266]	_	_
29-35	5653-5658	group	animal[266]	giv[266]	_	_
29-36	5659-5660	.	_	_	_	_

#Text=Here we address this problem in the context of signal detection theory and ML frameworks .
30-1	5661-5665	Here	_	_	_	_
30-2	5666-5668	we	person	giv	ana	31-6
30-3	5669-5676	address	_	_	_	_
30-4	5677-5681	this	abstract[268]	giv[268]	_	_
30-5	5682-5689	problem	abstract[268]	giv[268]	_	_
30-6	5690-5692	in	_	_	_	_
30-7	5693-5696	the	abstract[269]	new[269]	_	_
30-8	5697-5704	context	abstract[269]	new[269]	_	_
30-9	5705-5707	of	abstract[269]	new[269]	_	_
30-10	5708-5714	signal	abstract[269]|abstract|abstract[271]|abstract[272]	new[269]|giv|giv[271]|giv[272]	_	_
30-11	5715-5724	detection	abstract[269]|abstract[271]|abstract[272]	new[269]|giv[271]|giv[272]	_	_
30-12	5725-5731	theory	abstract[269]|abstract[272]	new[269]|giv[272]	_	_
30-13	5732-5735	and	abstract[269]	new[269]	_	_
30-14	5736-5738	ML	abstract[269]|abstract|abstract[274]	new[269]|giv|new[274]	_	_
30-15	5739-5749	frameworks	abstract[269]|abstract[274]	new[269]|new[274]	_	_
30-16	5750-5751	.	_	_	_	_

#Text=To illustrate the feasibility of our proposed approach in clinical diagnostics , results from simulation studies and tests of two available methylome datasets from leukemia and autism patients are presented and discussed .
31-1	5752-5754	To	_	_	_	_
31-2	5755-5765	illustrate	_	_	_	_
31-3	5766-5769	the	abstract[275]	new[275]	_	_
31-4	5770-5781	feasibility	abstract[275]	new[275]	_	_
31-5	5782-5784	of	abstract[275]	new[275]	_	_
31-6	5785-5788	our	abstract[275]|person|abstract[277]	new[275]|giv|new[277]	coref	32-1[288_277]
31-7	5789-5797	proposed	abstract[275]|abstract[277]	new[275]|new[277]	_	_
31-8	5798-5806	approach	abstract[275]|abstract[277]	new[275]|new[277]	_	_
31-9	5807-5809	in	abstract[275]	new[275]	_	_
31-10	5810-5818	clinical	abstract[275]|abstract[278]	new[275]|giv[278]	_	_
31-11	5819-5830	diagnostics	abstract[275]|abstract[278]	new[275]|giv[278]	_	_
31-12	5831-5832	,	_	_	_	_
31-13	5833-5840	results	abstract[279]	new[279]	_	_
31-14	5841-5845	from	abstract[279]	new[279]	_	_
31-15	5846-5856	simulation	abstract[279]|abstract|abstract[281]	new[279]|giv|new[281]	_	_
31-16	5857-5864	studies	abstract[279]|abstract[281]	new[279]|new[281]	_	_
31-17	5865-5868	and	abstract[279]	new[279]	_	_
31-18	5869-5874	tests	abstract[279]|abstract[282]	new[279]|giv[282]	_	_
31-19	5875-5877	of	abstract[279]|abstract[282]	new[279]|giv[282]	_	_
31-20	5878-5881	two	abstract[279]|abstract[282]|abstract[284]	new[279]|giv[282]|new[284]	_	_
31-21	5882-5891	available	abstract[279]|abstract[282]|abstract[284]	new[279]|giv[282]|new[284]	_	_
31-22	5892-5901	methylome	abstract[279]|abstract[282]|abstract|abstract[284]	new[279]|giv[282]|new|new[284]	_	_
31-23	5902-5910	datasets	abstract[279]|abstract[282]|abstract[284]	new[279]|giv[282]|new[284]	_	_
31-24	5911-5915	from	abstract[279]|abstract[282]|abstract[284]	new[279]|giv[282]|new[284]	_	_
31-25	5916-5924	leukemia	abstract[279]|abstract[282]|abstract[284]|abstract|person[287]	new[279]|giv[282]|new[284]|new|new[287]	_	_
31-26	5925-5928	and	abstract[279]|abstract[282]|abstract[284]|person[287]	new[279]|giv[282]|new[284]|new[287]	_	_
31-27	5929-5935	autism	abstract[279]|abstract[282]|abstract[284]|abstract|person[287]	new[279]|giv[282]|new[284]|new|new[287]	_	_
31-28	5936-5944	patients	abstract[279]|abstract[282]|abstract[284]|person[287]	new[279]|giv[282]|new[284]|new[287]	_	_
31-29	5945-5948	are	_	_	_	_
31-30	5949-5958	presented	_	_	_	_
31-31	5959-5962	and	_	_	_	_
31-32	5963-5972	discussed	_	_	_	_
31-33	5973-5974	.	_	_	_	_

#Text=This approach is implemented in the R package Methyl-IT , available at GitHub : https://github.com/genomaths/MethylIT .
32-1	5975-5979	This	abstract[288]	giv[288]	_	_
32-2	5980-5988	approach	abstract[288]	giv[288]	_	_
32-3	5989-5991	is	_	_	_	_
32-4	5992-6003	implemented	_	_	_	_
32-5	6004-6006	in	_	_	_	_
32-6	6007-6010	the	abstract[290]|abstract[291]	new[290]|giv[291]	coref	32-6[291_290]
32-7	6011-6012	R	person|abstract[290]|abstract[291]	new|new[290]|giv[291]	coref	33-2
32-8	6013-6020	package	abstract[290]|abstract[291]	new[290]|giv[291]	_	_
32-9	6021-6030	Methyl-IT	abstract[290]|abstract[291]	new[290]|giv[291]	_	_
32-10	6031-6032	,	abstract[290]|abstract[291]	new[290]|giv[291]	_	_
32-11	6033-6042	available	abstract[290]|abstract[291]	new[290]|giv[291]	_	_
32-12	6043-6045	at	_	_	_	_
32-13	6046-6052	GitHub	organization	new	_	_
32-14	6053-6054	:	_	_	_	_
32-15	6055-6092	https://github.com/genomaths/MethylIT	abstract	new	_	_
32-16	6093-6094	.	_	_	_	_

#Text=The R scripts to reproduce these analyses are available at the PSU GitLab : https://git.psu.edu/genomath/MethylIT_examples .
33-1	6095-6098	The	abstract[295]	new[295]	_	_
33-2	6099-6100	R	person|abstract[295]	giv|new[295]	_	_
33-3	6101-6108	scripts	abstract[295]	new[295]	_	_
33-4	6109-6111	to	abstract[295]	new[295]	_	_
33-5	6112-6121	reproduce	abstract[295]	new[295]	_	_
33-6	6122-6127	these	abstract[295]|abstract[296]	new[295]|new[296]	_	_
33-7	6128-6136	analyses	abstract[295]|abstract[296]	new[295]|new[296]	_	_
33-8	6137-6140	are	_	_	_	_
33-9	6141-6150	available	_	_	_	_
33-10	6151-6153	at	_	_	_	_
33-11	6154-6157	the	abstract[298]	new[298]	appos	33-15[0_298]
33-12	6158-6161	PSU	organization|abstract[298]	new|new[298]	_	_
33-13	6162-6168	GitLab	abstract[298]	new[298]	_	_
33-14	6169-6170	:	_	_	_	_
33-15	6171-6217	https://git.psu.edu/genomath/MethylIT_examples	abstract	giv	_	_
33-16	6218-6219	.	_	_	_	_
